# Dishman Carbogen Amcis Ltd (DCAL)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹199.83
Day Change: +2.28%
52W High: ₹321.95
52W Low: ₹128.5
Market Cap: ₹2,939 Cr

## Valuation
P/E: 24.73
P/B: 0.46
EPS: ₹7.58
Book Value: ₹405.67
Dividend Yield: 0%

## Returns
1Y Return: -21.6%

## Profitability
ROE: 0%
ROCE: 6.2%
Debt/Equity: 0.4
Revenue Growth: 5.5%
Profit Growth: 0%
EBITDA Margin: 17.3%
Operating Margin: 3.99%

## About
Dishman Carbogen Amcis Ltd is a Biotechnology company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Biotechnology
Sub Industry: Unknown

## Business Model
Overview: Dishman Carbogen Amcis Ltd makes money through Technology services, Digital transformation projects, Maintenance and managed services in Biotechnology. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Technology services
- Digital transformation projects
- Maintenance and managed services
Operating Model:
- Wins client contracts, deploys skilled delivery teams, and earns project or recurring service revenue.
- Utilisation, billing rates, attrition, and currency movements are key operating levers.
Recent Context:
- Announcement: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Quarterly Report: Board Meeting Intimation for Considering, Take On Record & Approve The Audited Financial Results Of The Company For The Quarter And Year Ended 31/03/2026 & To Consider, Evaluate And Approve The Proposal Of Availing ECB In The Form Of Unsecured Loan(S) From Promoter Group Company
- BSE Filing: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

## Access
Current tier: anonymous
More history: Register free to see 7 more years.

## Data Freshness
Quote Updated: 2026-05-25T20:00:13.927Z
Price History Updated: 2026-05-25T05:31:26.688Z
Latest Price History Date: 2026-05-24
Technicals Updated: 2026-05-25T05:31:26.688Z
Quant Updated: 2026-05-25T05:31:26.688Z
Sentiment Updated: 2026-05-25T05:31:26.688Z
Financials Status: current
Financials Updated: 2026-05-18T15:31:15.657Z
Financials Last Attempt: 2026-05-18T15:31:15.657Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2017)
Revenue: ₹1031 Cr
Operating Profit: ₹201 Cr (OPM 20%)
Net Profit: ₹80 Cr
Tax: ₹91 Cr

## Annual P&L History
Mar 2017: Rev ₹1031Cr | PAT ₹80Cr | OPM 20%
Mar 2018: Rev ₹1714Cr | PAT ₹145Cr | OPM 26%
Mar 2019: Rev ₹1695Cr | PAT ₹155Cr | OPM 26%

## Balance Sheet (Mar 2017)
Total Assets: ₹2081 Cr
Total Liabilities: ₹2081 Cr
Borrowings: ₹868 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Arpit Janmejay Vyas, Global MD & Director
- Deohooti Janmejay Vyas, Whole Time Director
- Harshil R. Dalal, Global Chief Financial Officer
- Paolo  Armanino, Chief Operating Officer of Indian Operations
- Shrima Gaurangbhai Dave, Compliance Officer & Company Secretary

---
Source: rupiya.io/stocks/dcal
Disclaimer: For research and education only. Not investment advice.